BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8873054)

  • 1. Complete responses and survival after polychemotherapy plus interferon-alpha for patients with metastatic melanoma.
    Vuoristo MS
    Melanoma Res; 1996 Aug; 6(4):331-6. PubMed ID: 8873054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
    Vuoristo MS; Hahka-Kemppinen M; Parvinen LM; Pyrhönen S; Seppä H; Korpela M; Kellokumpu-Lehtinen P
    Melanoma Res; 2005 Aug; 15(4):291-6. PubMed ID: 16034308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.
    Kivelä T; Suciu S; Hansson J; Kruit WH; Vuoristo MS; Kloke O; Gore M; Hahka-Kemppinen M; Parvinen LM; Kumpulainen E; Humblet Y; Pyrhönen S
    Eur J Cancer; 2003 May; 39(8):1115-20. PubMed ID: 12736111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of metastatic melanoma treated with a combination of interferon alfa 2b, dacarbazine and nimustine.
    Gröhn P; Kumpulainen E; Nuortio L; Hakala T; Vuoristo MS; Korpela M; Heikkinen M; Salmi R; Jakobsson M; Numminen S
    Eur J Cancer; 1992; 28(2-3):441-3. PubMed ID: 1591060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
    Punt CJ; van Herpen CM; Jansen RL; Vreugdenhil G; Muller EW; de Mulder PH
    Br J Cancer; 1997; 76(2):266-9. PubMed ID: 9231931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent interferon and polychemotherapy in metastatic melanoma.
    Vuoristo MS; Gröhn P; Kellokumpu-Lehtinen P; Kumpulainen E; Turunen M; Korpela M; Joensuu H; Tiusanen K; Nevantaus A
    J Cancer Res Clin Oncol; 1995; 121(3):175-80. PubMed ID: 7536196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma.
    Pyrhönen S; Hahka-Kemppinen M; Muhonen T
    J Clin Oncol; 1992 Dec; 10(12):1919-26. PubMed ID: 1280673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
    Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
    Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dacarbazine, vincristine, bleomycin and lomustine plus natural interferon-alpha for metastatic melanoma.
    Reinhold U; Bruske T; Kreysel HW
    Eur J Cancer; 1996 Jan; 32A(1):180. PubMed ID: 8695233
    [No Abstract]   [Full Text] [Related]  

  • 11. Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma.
    York RM; Foltz AT
    Cancer; 1988 Jun; 61(11):2183-6. PubMed ID: 2452681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy.
    Nathan FE; Berd D; Sato T; Shield JA; Shields CL; De Potter P; Mastrangelo MJ
    J Exp Clin Cancer Res; 1997 Jun; 16(2):201-8. PubMed ID: 9261748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunochemotherapy with recombinant interferon-alpha 2b plus dacarbazine in the treatment of advanced malignant melanoma.
    Strojan P; Rudolf Z
    Melanoma Res; 1997 Oct; 7(5):420-7. PubMed ID: 9429226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy.
    Hahka-Kemppinen M; Muhonen T; Virolainen M; Jekunen A; Asko-Seljavaara S; Pyrhönen S
    Br J Dermatol; 1995 Jun; 132(6):973-7. PubMed ID: 7544996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A feasibility study using polychemotherapy (cisplatin + vindesine + dacarbazine) plus interferon-alpha or monochemotherapy with dacarbazine plus interferon-alpha in metastatic melanoma.
    Bajetta E; Del Vecchio M; Vitali M; Martinetti A; Ferrari L; Queirolo P; Sertoli MR; Cainelli T; Cellerino R; Cascinelli N
    Tumori; 2001; 87(4):219-22. PubMed ID: 11693798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group.
    Cancer; 1989 May; 63(9):1676-80. PubMed ID: 2467736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dacarbazine and interferon-alpha 2a in advanced malignant melanoma: high response rate and prolongation of response duration occur in different patient subpopulations.
    Betticher DC; Lee SM; Morris C; Clemons M; Thatcher N
    Melanoma Res; 1995 Aug; 5(4):277-82. PubMed ID: 7496165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
    Falkson CI; Ibrahim J; Kirkwood JM; Coates AS; Atkins MB; Blum RH
    J Clin Oncol; 1998 May; 16(5):1743-51. PubMed ID: 9586887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.